1. Medtech Insight

Exec Chat: Pear Therapeutics’ CEO Charts Future For Digital Therapeutics Following SPAC Deal

 
• By Reed Miller

Pear has commercialized FDA-cleared prescription digital therapeutics for substance abuse disorder, opioid use disorder and chronic insomnia and has 14 more in development. CEO Corey McCann explained Pear’s vision for how PDTs can transform health care.

Woman using a prescription digital therapeutic developed by Pear Therapeutics
• Source: Pear Therapeutics

Pear Therapeutics, Inc. reached a critical milestone in its plan to pioneer the emerging market for prescription digital therapeutics (PDT).

On 22 June, Pear announced plans to become a publicly traded company via a merger with a special purpose acquisition company (SPAC). Pear will merge with Thimble Point Acquisition Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business